- Identification of emergent genomic alterations of interest due to increased testing and population analysis
- Identification of emergent genomic alterations of interest due to increased testing and population analysis
- Identification of emergent genomic alterations of interest due to increased testing and population analysis
If you are interested in collaborating to advance the general understanding and clinical relevance of genomic testing for cancer, we would love to hear from you.
Get in touch today at info@elevationoncology.com
Industry Highlights
“Precise therapy development is needed to ensure that patients and their physicians have treatment options that make their genomic test results actionable.”
We believe that genomic testing is critical to ensuring that patients receive their best chance at improved outcomes. Knowing whether your tumor has a driver mutation can help your doctor best guide your treatment plans.
Ask your doctor today about your options for genomic testing, and whether you may be eligible for an approved targeted therapy or a clinical trial. Here are a few downloadable resources to help you start the discussion.
We hope that our experiences can inspire and support others embarking on a similar drug development journey.
While each driver alteration may individually be rare, our combined efforts as part of a vibrant precision medicine community can enable a future where every patient’s cancer genomic test results in an actionable treatment decision.
